Warner Chilcott

Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes

Retrieved on: 
Tuesday, March 19, 2024
Growth, Information technology, Central nervous system, General counsel, Warner Chilcott, CNS, Senior, Davis Polk, Therapy, Corporate development, Management

Mr. Halstead is currently serving as Executive Vice President and General Counsel.

Key Points: 
  • Mr. Halstead is currently serving as Executive Vice President and General Counsel.
  • In this newly created leadership role, Mr. Halstead will oversee several functions within the Company including legal, human resources, manufacturing & supply chain, quality, compliance, information technology, and external innovation.
  • “Michael is an exceptional leader who has been instrumental in Intra-Cellular Therapies’ strong growth over the last decade,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.
  • He joined Intra-Cellular Therapies in 2014 as Senior Vice President and General Counsel and was promoted to Executive Vice President and General Counsel in 2019.

Lexicon Strengthens Management Team With Two New Executives

Retrieved on: 
Tuesday, October 31, 2023
Knowledge, National Investor Relations Institute, Professional corporation, Bristol Myers Squibb, Melinta Therapeutics, Policy, AbbVie, Lexicon, Therapy, Ophthalmology, Actavis, Intercept, BS, Seton Hall University, Ozanimod, University, Amarin, Warner Chilcott, MBA, Ladenburg Thalmann, Alemtuzumab, Allergan, Business administration, Marketing, Wall Street, Watson Labs, Villalba v Merrill Lynch & Co Inc, Sclerosis, Heart failure, Intercept Pharmaceuticals, Pharmaceutical industry

THE WOODLANDS, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Matthew Cullen is joining the company as vice president of value and access, effective November 1, 2023, and Lisa DeFrancesco will join as head of investor relations and corporate strategy, effective November 13, 2023.

Key Points: 
  • Mr. Cullen brings Lexicon more than 35 years of industry experience in market access and sales leadership.
  • Before joining Lexicon, Matt served as vice president, value, access and policy at Apellis Pharmaceuticals where he led the market access launch of rare disease drug EMPAVELI® (pegcetacoplan) and ophthalmology drug SYFOVRE® (pegcetacoplan injection).
  • His responsibilities included pricing and contracting, payer strategy and marketing, corporate and strategic account management, field reimbursement, trade and distribution, and training.
  • Prior to Apellis, Mr. Cullen led strategic payer marketing and access teams at Bristol-Myers Squibb for ELIQUIS® (apixaban) and ORENCIA® (abatacept).

Replimune Announces Appointment of Emily Hill as Chief Financial Officer

Retrieved on: 
Tuesday, September 19, 2023
Actavis, PTC Therapeutics, Senior, Fordham University, Partner, Biotechnology, PTC, MBA, Biomedical Research, Hamilton College, Summer Street (Boston), CFO, Warner Chilcott, Growth, Therapy, Financial management, Pharmaceutical industry, Management, Science, Genzyme, Finance, Pharmacology

WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the appointment of Emily Hill as Chief Financial Officer.

Key Points: 
  • WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the appointment of Emily Hill as Chief Financial Officer.
  • “Emily brings a wealth of financial planning and strategy experience to Replimune that will be impactful as we look to transition to a commercial stage company,” said Philip Astley-Sparke, CEO of Replimune.
  • “I'm looking forward to applying my expertise and experience to help Replimune continue its growth and make the transition from a clinical to commercial stage company.”
    Prior to joining Replimune, Emily held numerous positions at PTC Therapeutics where she headed up Investor Relations before becoming the Company’s Chief Financial Officer.
  • Emily was heavily involved in PTC’s evolution from a development stage company to a five product company generating revenues approaching $1billion.

Global Medical Tubing Market Analysis Report 2023-2030: Manufacturers Seeking Collaborations to Help Spur Innovative Solutions - ResearchAndMarkets.com

Retrieved on: 
Monday, July 31, 2023
Health, Medical Supplies, Medical Devices, Infection, Tissue, Insurance, Silicone, Asthma, TPE, Prevalence, Diabetes, Wyeth, Arthritis, Administration, Estradiol acetate, Freudenberg, Cancer, Lung cancer, Needle, Nordson Corporation, Instrument, Noetics, USD, NDC, Pulmonary fibrosis, Silicon, Back pain, Acquisition, Medicaid, Warner Chilcott, Conditional sentence, Growth, WHO, Chronic obstructive pulmonary disease, NHE, Ministry, World Health Organization, Syringe, Dietary supplement, Pharmaceutical industry, Levonorgestrel-releasing implant

The "Medical Tubing Market Size, Share & Trends Analysis Report By Product Type (Silicone, Polyolefins, Polyimide), By Application (Bulk Disposable Tubing), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Tubing Market Size, Share & Trends Analysis Report By Product Type (Silicone, Polyolefins, Polyimide), By Application (Bulk Disposable Tubing), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global medical tubing market size is anticipated to reach USD 19,498.5 million by 2030.
  • These factors are anticipated to fuel the growth of medical tubing product demand over the forecast period.
  • Medical tubing manufacturers are seeking collaborations, mergers, and acquisitions to develop advanced and innovative solutions.

Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality

Retrieved on: 
Sunday, January 22, 2023
General counsel, Warner Chilcott, CMC, Regulatory News Service, Master of Pharmacy, CET, United States Department of the Navy, Pharmacovigilance, MD, Johnson & Johnson, Pfizer, Good laboratory practice, Good manufacturing practice, Capsule, Eastern University, Sri Lanka, NDA, BA, Good clinical laboratory practice, Patient, Organization, Regulatory affairs, SLT, Therapy, Charcot–Marie–Tooth disease, Cellectis, Eastern University, Master of Science, Quality assurance, Tablet, Scott, Bachelor of Science, Gan, Doctor of Philosophy, Neurodegeneration, Hugo, Management, Pharmaceutical industry, Medical device, Sanofi, Quality

Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality

Key Points: 
  • Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
    PARIS, France, January 4th, 2023, 08:30 am CET – Pharnext SA (FR001400BV89 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the appointment of Scott Johnson as VP, Head of Quality.
  • Prior to Oyster, Scott served as Director, Quality Assurance at Lupin Pharmaceuticals where he had overall responsibility for quality and compliance.
  • Hugo Brugière, Chairman and Chief Executive Officer of Pharnext, commented: “I look forward to working with Scott and am delighted to welcome him to the Pharnext Senior Leadership Team.

Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors

Retrieved on: 
Tuesday, October 12, 2021
Company, NDA, Migraine, Therapy, Risk, Doctor of Philosophy, Dihydroergotamine, SAN, Special counsel, Davis Polk & Wardwell, Plasma, DHE, COVID-19, Mergers and acquisitions, General counsel, GLOBE, JD, Safety, Board of directors, ASCEND, Board, Terminology, Legal Affairs, U.S. Securities and Exchange Commission, University, Assistant, Berkeley, Â, Security (finance), Triangle Park (Quezon City), Senior, Achievement, Warner Chilcott, Patient, Cooley, Wardwell, BA, Nasdaq, Cooley LLP, Pharmaceutical industry, Risk management

Ms. Harsch is a highly regarded and established pharmaceutical industry professional who brings over 20 years of legal, corporate governance, corporate transaction, and operating experience to Satsuma.

Key Points: 
  • Ms. Harsch is a highly regarded and established pharmaceutical industry professional who brings over 20 years of legal, corporate governance, corporate transaction, and operating experience to Satsuma.
  • We are pleased to welcome Ms. Harsch to Satsumas Board and look forward to benefitting from her experience and guidance as we advance STS101 through Phase 3 development and toward commercialization, stated Heath Lukatch, PhD, Chairman of Satsumas Board of Directors.
  • Ms. Harsch commented, It is an honor to join Satsumas Board at this pivotal juncture in the companys development.
  • Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product, STS101, for the acute treatment of migraine.

Steve Kurzeja Named Chief Revenue Officer of Life Sciences Tech Innovator P360

Retrieved on: 
Wednesday, October 6, 2021
Other Professional Services, Data Management, Technology, Marketing, Pharmaceutical, Communications, Professional Services, General Health, Other Technology, Science, Software, Networks, Other Science, Internet, Health, Bausch Health, Therapy, Commercial Operating System (COS), Kyowa Hakko Kirin, Warner–Lambert, SMS, HCPS, Multimedia, Patient, Degenerative disease, Communication, Marketing, Industry, Growth, Technology, Pfizer, Unified communications as a service, CRO, Actavis, HCP, Warner Chilcott, Pharmaceutical industry, Mobile phone

P360 , a leading developer of technology for life sciences companies, today announced that veteran pharmaceutical industry executive Steve Kurzeja was appointed the companys first chief revenue officer (CRO).

Key Points: 
  • P360 , a leading developer of technology for life sciences companies, today announced that veteran pharmaceutical industry executive Steve Kurzeja was appointed the companys first chief revenue officer (CRO).
  • View the full release here: https://www.businesswire.com/news/home/20211006005006/en/
    P360 Chief Revenue Officer Steve Kurzeja (Photo: Business Wire)
    Steves vast experience leading revenue-generating initiatives for pharmaceutical companies makes him the perfect fit to serve as chief revenue officer of P360, stated P360 CEO and Founder Anupam Nandwana.
  • I am thrilled to be joining such an innovative and passionate group of industry disruptors, said P360 Chief Revenue Officer Steve Kurzeja.
  • The appointment of Steve Kurzeja as chief revenue officer comes just as P360 announced that its ZING Communication Module has been enhanced with several new enterprise-grade unified communication features.